Jazz Pharmaceuticals Completes Biologics License Application for Zanidatamab for HER2-Positive Metastatic Biliary Tract Cancer

Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States.

Source link
#Jazz #Pharmaceuticals #Completes #Biologics #License #Application #Zanidatamab #HER2Positive #Metastatic #Biliary #Tract #Cancer